Conference call on Interim Report
Invitation to attend XVIVO Perfusion’s conference call regarding the presentation of the interim report January - March 2019. The presentation will be held in English.
Time: Wednesday, April 24, 2019 at 2.00 p.m. CET
Information regarding the conference can be found under the following link:
https://financialhearings.com/event/11911
Phone numbers to the conference:
Sweden dial in number: +46 (0)8 5055 8356
USA dial in number: +1 833 823 0590
International dial in number: +44 (0) 3333 009 031
Participants from XVIVO Perfusion:
Magnus Nilsson, CEO
Christoffer Rosenblad, CFO
The press release for XVIVO Perfusion’s interim report January – March 2019 will be released on April 24, 2019 at 7:30 a.m. CET.
Before the conference call, slides will be available at the company web page, www.xvivoperfusion.com/corporate/.
April 16, 2019
Gothenburg
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +46 735 192159, christoffer.rosenblad@xvivoperfusion.com
Magnus Nilsson, CEO, +46 31-788 21 50, e-post: magnus.nilsson@xvivoperfusion
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
______________________________________________________________________________________________________________________
XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden and one office in Denver, the USA. The XVIVO share is listed on Nasdaq Stockholm and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com.
______________________________________________________________________________________________________________________
XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com
Tags: